EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice

Jakob E Ostberg, Zeeshan Ahmed, Katayoun Saatchi, Parleen K Pandher iD, Yamna Rahim, Urs O Häfeli iD, Sarah L Gray iD

Obesity · 2026-05 · 34 (5) · 1068-1080

DOI: 10.1002/oby.70182 ↗

At a glance

Journal article in Obesity, published online on 2026-03-31. Written by Jakob E Ostberg and 6 co-authors. Institution: Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada. Major MEDLINE topics: Rosiglitazone, Insulin Resistance, Magnetic Iron Oxide Nanoparticles, Obesity. Cited 1 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: New Frontiers in Research Fund - Expoloration, Tier 2 Canada Research Chair - Integrative Physiology of Diabetes, CIHR.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

This study aimed to assess iron oxide magnetic nanoparticles (MNPs) for adipose tissue‐targeted therapeutics to restore adipose tissue function and insulin sensitivity in obesity.

Methods

The insulin‐sensitizing effects of rosiglitazone and known adverse effects were leveraged for this proof‐of‐concept assessment of adipose tissue drug targeting. Rosiglitazone was adsorbed to alendronic acid‐coated MNPs (rosiMNPs) and a biocompatible magnet implanted in the right inguinal white adipose tissue (ingWAT) of obese, insulin resistant male mice. Following rosiMNP treatment (1.5 mg/kg/day, 18 days), insulin sensitivity and adipose tissue health were assessed.

Results

RosiMNPs restored insulin sensitivity as well as systemic rosiglitazone (1.5 mg/kg/day, 18 days), with a shift in adipocyte size compatible with PPARγ‐induced adipocyte hyperplasia and no increase in circulating adiponectin. PPARγ target genes were induced in ingWAT with rosiMNPs or systemic rosiglitazone, but only in liver and gonadal WAT of systemically treated mice. Additionally, iron accumulation was shown in the right, targeted ingWAT depot, but not in the left, untargeted ingWAT, kidney, or liver, suggesting targeting was achieved. Unfortunately, the dose and duration of systemic treatment were ineffective at inducing changes in kidney.

Conclusions

Results demonstrate the potential benefits of adipose tissue‐targeted therapeutics to improve adipose tissue function to restore insulin sensitivity to prevent the metabolic complications of obesity.

Subjects

MeSH terms (MEDLINE)

RosiglitazoneInsulin ResistanceMagnetic Iron Oxide NanoparticlesObesityAdipose Tissue, WhiteHypoglycemic AgentsThiazolidinedionesAdipose TissueAnimalsMaleMicePPAR-gamma AgonistsPPAR gammaAdipocytesMice, Inbred C57BLAdiponectinDrug Delivery Systems

Author keywords

PPAR gammaadipose tissueinsulin resistancenanotechnologyobesity

Substances

RosiglitazonePPAR-gamma AgonistsPPAR gammaHypoglycemic AgentsAdiponectinThiazolidinediones

Authors and institutions

  • Division of Medical Sciences, University of Northern British Columbia, Prince George, British Columbia, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID profiles: Parleen K Pandher, Urs O Häfeli, Sarah L Gray

Funding

  • New Frontiers in Research Fund - Expoloration
  • Tier 2 Canada Research Chair - Integrative Physiology of Diabetes
  • CIHR
  • Natural Sciences and Engineering Research Council of Canada
  • University of Northern British Columbia
  • Canadian Institutes of Health Research

Cite

APA

Ostberg, J. E., Ahmed, Z., Saatchi, K., Pandher, P. K., Rahim, Y., Häfeli, U. O., & Gray, S. L. (2026). Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity, 34(5), 1068-1080. https://doi.org/10.1002/oby.70182

Vancouver

Ostberg JE, Ahmed Z, Saatchi K, Pandher PK, Rahim Y, Häfeli UO, et al. Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice. Obesity. 2026;34(5):1068-1080. doi:10.1002/oby.70182

BibTeX
@article{Ostberg2026,
  author = {Ostberg, Jakob E and Ahmed, Zeeshan and Saatchi, Katayoun and Pandher, Parleen K and Rahim, Yamna and Häfeli, Urs O and Gray, Sarah L},
  title = {Adipose Tissue‐Targeted Delivery of Rosiglitazone With Iron Oxide Nanoparticles Ameliorates Insulin Resistance in Male Mice},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {1068--1080},
  doi = {10.1002/oby.70182}
}
Start for free →